secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001213900-23-063213
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals implements 1-for-25 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Reverse stock split effective Aug 4, 2023 at 11:59 p.m. ET; split-adjusted trading begins Aug 7.
- Outstanding shares reduce from ~30.5M to ~1.2M; no change in authorized shares.
- Proportional adjustments to equity awards and warrants; fractional shares cashed out.
- Primary goal: raise bid price above $1.00 to maintain Nasdaq listing.
- CEO Claiborne cites progress on AD04 for Alcohol Use Disorder and attracting broader investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023063213/0001213900-23-063213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023063213/ea182870-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-063213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer